Access keys

Skip to content Accessibility Home News, events and publications Site map Search Privacy policy Help Contact us Terms of use

Dying tumour cells release intracellular ions in a last-ditch attempt to block the immune system

Copyright: Beckie Port
News from: The Babraham Institute

Researchers at the National Cancer Institute in the USA and the Babraham Institute, UK, have discovered how a mineral ion leaked from tumour tissue as it dies acts to stop the work of anti-tumour immune cells. This discovery provides a new approach in the development of treatments to engage the immune system in the fight against cancer. 

Tumours consist of a mix of actively multiplying cells and areas of dead tissue. Previous research has found that tumours can repress the immune cells that act against them but until now, it wasn’t known how. New research, published online today in Nature, found that cells within tumours release potassium into the extracellular space upon dying. Potassium is an ion that is usually found at high concentrations within cells and not outside them. The increased level of potassium in the extracellular tumour environment dulled the activity of T cells, a specialised effector cell of the immune system, preventing their anti-tumour function.

The researchers molecularly engineered tumour-specific T cells to increase their capacity to remove potassium from the cell. This created T cells which could effectively function to stimulate an anti-tumour immune response despite the elevated potassium environment surrounding them. The cells were engineered to express more molecular pumps specifically to deport excess potassium from the cell. Boosting the cells’ ‘potassium export’ capabilities prevented the high levels of intracellular potassium accumulation responsible for cellular dysfunction.

Modifying the T cells in this way enhanced the clearance of tumours and survival rates in mice with skin cancer.

Dr Rahul Roychoudhuri, group leader in the Lymphocyte Signalling and Development programme at the Babraham Institute and an author on the paper, said: “While ions such as calcium are known to play critical roles in the activation of T cells when they encounter foreign invaders and cancer cells, very little was known about how extracellular potassium might affect this. Surprisingly, we found that high levels of potassium, which was released by dying cells in tumours, had very little effect on calcium but blocked activation of a cellular signalling pathway called the PI3K pathway when T cells encountered tumour antigens. We have a lot of experience studying the PI3K pathway at the Institute so were well positioned to help understand the mechanisms by which potassium was blocking T cell activation.”

This research uncovers a new mechanism by which tumours act to block anti-tumour function and identifies new target points for the design of new immune-based therapies for cancer. Dr Nicholas Restifo, lead author from the National Cancer Institute, said: "The findings provide new insights into how ionic imbalances in the tumour microenvironment can powerfully impede the functions of immune cells infiltrating tumours. We’re particularly excited about how this may help us to develop new therapies to activate immune function in cancer patients.”

The research was funded by the Intramural Research Programs of the National Cancer Institute and National Institutes of Health, USA and The Wellcome Trust. The Babraham Institute is strategically supported by the Biotechnology and Biological Sciences Research Council.

ENDS

Notes for editors

Publication reference: Eil & Vodnala et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 2016

About the Babraham Institute

The Babraham Institute, which receives strategic funding (a total of £21.2M in 2015-16) from the Biotechnology and Biological Sciences Research Council (BBSRC), undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The Institute’s research provides greater understanding of the biological events that underlie the normal functions of cells and the implication of failure or abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. www.babraham.ac.uk

About BBSRC

BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by government, BBSRC invested £473 million in world-class bioscience, people and research infrastructure in 2015-16. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.

More information about BBSRC, our science and our impact.
More information about BBSRC strategically funded institutes.


Tags: The Babraham Institute cancer disease human health research press release